Sana Biotechnology to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting
May 02 2022 - 4:35PM
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on
creating and delivering engineered cells as medicines, today
announced that five abstracts covering preclinical data from its
hypoimmune and fusogen platforms were accepted for either oral or
poster presentation at the American Society of Gene and Cell
Therapy (ASGCT) 25th Annual Meeting taking place May 16-19, 2022 in
Washington, D.C.
“We will have a strong presence at ASGCT, with presentations of
data from multiple technology platforms, including two oral
presentations on our hypoimmune platform and two posters on our
fusogen platform,” said Steve Harr, MD, Sana’s President and CEO.
“We remain excited with the progress we are making with these
platforms that are targeted to address some of the major challenges
faced in the field of gene and cell therapy. Our goal is to file
two INDs this year from two of these platforms, with the aim of
translating our exciting scientific progress into beneficial
therapeutics for patients.”
The ASGCT abstracts are available to the public at
https://annualmeeting.asgct.org.
Oral Presentations: |
Title: |
Hypoimmune mouse primary pancreatic islet cells survive and
functionally rescue allogeneic diabetic mice |
Summary: |
Hypoimmune islet cells
transplanted intramuscularly may be capable of persisting and
functioning in diabetic patients without immune suppression |
Abstract
Number: |
1244 |
Session: |
Cell Therapies for Hematological
Disorders |
Date/Time: |
Thursday, May 19, 2022 from 10:30
a.m. – 10:45 a.m. ET |
|
|
Title: |
Generation of
off-the-shelf allogeneic hypoimmune Tregs |
Summary: |
A method to genetically engineer
immune evasive “hypoimmune” regulatory T cells (Tregs) ex vivo
that, in the assays tested, are immune evasive, functional, and
protected from innate immune reactivity |
Abstract
Number: |
1254 |
Session: |
Cell Therapy Product Engineering,
Development or Manufacturing |
Date/Time: |
Thursday, May 19, 2022 from 11:15
a.m. – 11:30 a.m. ET |
Poster Presentations: |
Title: |
Retargeted “fusosomes” for in vivo delivery to T
cells |
Summary: |
In vivo delivery of a CD19 CAR
transgene payload with either CD8- or CD4-targeting vectors in
Nalm-6 tumor bearing mouse models demonstrated robust production
and persistence of CAR T cells, leading to tumor eradication |
Abstract
Number: |
1081 |
Session: |
Cancer – Immunotherapy, Cancer
Vaccines III |
Date/Time: |
Wednesday, May 18, 2022 from 5:30
p.m. – 6:30 p.m. |
|
|
Title: |
Fusosome-targeted gene
transfer to human hepatocytes |
Summary: |
Proof of principle data showing
efficient delivery of a reporter transgene to human hepatocytes in
vivo using a humanized liver mouse model |
Abstract
Number: |
875 |
Session: |
RNA Virus Vectors |
Date/Time: |
Wednesday, May 18, 2022 from 5:30
p.m. – 6:30 p.m. ET |
|
|
Title: |
A novel VCN assay that
detects lentiviral vector integrations while overcoming limitations
caused by plasmid residuals |
Summary: |
Data from a novel assay that
relies on a unique amplicon and droplet digital PCR process that is
specific to only reverse-transcribed self-inactivating viral vector
nucleic acids |
Abstract
Number: |
M-305 |
Session: |
Pharmacology / Toxicology Studies
or Assay Development |
Date/Time: |
Monday, May 16, 2022 from 5:30
p.m. – 6:30 p.m. ET |
About Hypoimmune PlatformSana’s hypoimmune
platform is designed to create cells ex vivo that can “hide” from
the patient’s immune system to enable the transplant of allogeneic
cells without the need for immunosuppression. We are applying the
hypoimmune technology to both pluripotent stem cells, which can
then be differentiated into multiple cell types, and to
donor-derived allogeneic T cells, with the goal of making potent
and persistent CAR T cells at scale. Preclinical data demonstrates
across a variety of cell types that these transplanted allogeneic
cells are able to evade both the innate and adaptive arms of the
immune system while retaining their activity. Our most advanced
programs utilizing this platform include an allogeneic CAR T
program targeting CD19+ cancers and stem-cell derived pancreatic
cells for patients with type 1 diabetes.
About Fusogen PlatformSana is developing
re-targetable fusogens as a platform technology to enable the in
vivo delivery of genetic payloads to specific cell types. Fusogens
can bind to cell-surface proteins on the target cell type and, when
combined with delivery vehicles to form fusosomes, deliver a
genetic payload directly to the cell’s cytoplasm. We have shown in
preclinical studies that we can engineer fusogens to specifically
target diverse cell surface receptors that allow cell-specific
delivery across multiple different cell types. Our most advanced
programs utilizing this platform include in vivo CAR T cell
fusosome product candidates targeting CD19+ cancer cells, including
non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute
lymphocytic leukemia.
About Sana BiotechnologySana Biotechnology,
Inc. is focused on creating and delivering engineered cells as
medicines for patients. We share a vision of repairing and
controlling genes, replacing missing or damaged cells, and making
our therapies broadly available to patients. We are a passionate
group of people working together to create an enduring company that
changes how the world treats disease. Sana has operations in
Seattle, Cambridge, South San Francisco, and Rochester. For more
information about Sana Biotechnology, please visit
https://sana.com/.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements about Sana Biotechnology, Inc. (the “Company,” “we,”
“us,” or “our”) within the meaning of the federal securities laws,
including those related to the company’s vision, progress, and
business plans; expectations for its development programs, product
candidates and technology platforms, including its pre-clinical,
clinical and regulatory development plans and timing expectations;
the Company’s participation in the 2022 American Society of Gene
& Cell Therapy meeting and the subject matter of the Company’s
presentations at that meeting; the potential ability to make
hypoimmune-modified pluripotent stem cells and donor-derived
allogeneic T cells that survive and evade the immune system without
immunosuppression and the potential efficacy of such hypoimmune
cells; and the potential ability to engineer re-targetable fusogens
that specifically target cell surface receptors that, combined with
delivery vehicles, allow cell-specific delivery across different
cell types. All statements other than statements of historical
facts contained in this press release, including, among others,
statements regarding the Company’s strategy, expectations, cash
runway and future financial condition, future operations, and
prospects, are forward-looking statements. In some cases, you can
identify forward-looking statements by terminology such as “aim,”
“anticipate,” “assume,” “believe,” “contemplate,” “continue,”
“could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,”
“may,” “objective,” “plan,” “positioned,” “potential,” “predict,”
“seek,” “should,” “target,” “will,” “would” and other similar
expressions that are predictions of or indicate future events and
future trends, or the negative of these terms or other comparable
terminology. The Company has based these forward-looking statements
largely on its current expectations, estimates, forecasts and
projections about future events and financial trends that it
believes may affect its financial condition, results of operations,
business strategy and financial needs. In light of the significant
uncertainties in these forward-looking statements, you should not
rely upon forward-looking statements as predictions of future
events. These statements are subject to risks and uncertainties
that could cause the actual results to vary materially, including,
among others, the risks inherent in drug development such as those
associated with the initiation, cost, timing, progress and results
of the Company’s current and future research and development
programs, preclinical and clinical trials, as well as the economic,
market and social disruptions due to the ongoing COVID-19 public
health crisis. For a detailed discussion of the risk factors that
could affect the Company’s actual results, please refer to the risk
factors identified in the Company’s SEC reports, including but not
limited to its Annual Report on Form 10-K dated March 16, 2022.
Except as required by law, the Company undertakes no obligation to
update publicly any forward-looking statements for any reason.
Investor Relations & Media:Nicole
KeithInvestor.relations@sana.com media@sana.com
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
From Jul 2023 to Jul 2024